IRIDEX Corporation
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and Oc… Read more
IRIDEX Corporation (IRIX) - Net Assets
Latest net assets as of September 2025: $4.68 Million USD
Based on the latest financial reports, IRIDEX Corporation (IRIX) has net assets worth $4.68 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($28.35 Million) and total liabilities ($23.67 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.68 Million |
| % of Total Assets | 16.51% |
| Annual Growth Rate | -2.74% |
| 5-Year Change | -87.92% |
| 10-Year Change | -93.78% |
| Growth Volatility | 70.43 |
IRIDEX Corporation - Net Assets Trend (1995–2024)
This chart illustrates how IRIDEX Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for IRIDEX Corporation (1995–2024)
The table below shows the annual net assets of IRIDEX Corporation from 1995 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $2.10 Million | -77.98% |
| 2023-12-31 | $9.52 Million | -44.74% |
| 2022-12-31 | $17.23 Million | -26.04% |
| 2021-12-31 | $23.30 Million | +34.16% |
| 2020-12-31 | $17.37 Million | -23.51% |
| 2019-12-31 | $22.70 Million | -24.22% |
| 2018-12-31 | $29.96 Million | -1.84% |
| 2017-12-31 | $30.52 Million | -22.06% |
| 2016-12-31 | $39.16 Million | +16.24% |
| 2015-12-31 | $33.69 Million | -0.14% |
| 2014-12-31 | $33.74 Million | +30.49% |
| 2013-12-31 | $25.85 Million | +18.03% |
| 2012-12-31 | $21.91 Million | -2.32% |
| 2011-12-31 | $22.43 Million | +15.44% |
| 2010-12-31 | $19.43 Million | +29.29% |
| 2009-12-31 | $15.03 Million | +27.92% |
| 2008-12-31 | $11.75 Million | -37.55% |
| 2007-12-31 | $18.81 Million | -41.51% |
| 2006-12-31 | $32.16 Million | -6.84% |
| 2005-12-31 | $34.52 Million | +8.60% |
| 2004-12-31 | $31.78 Million | +3.08% |
| 2003-12-31 | $30.83 Million | +2.11% |
| 2002-12-31 | $30.20 Million | +1.22% |
| 2001-12-31 | $29.83 Million | -2.19% |
| 2000-12-31 | $30.50 Million | +10.89% |
| 1999-12-31 | $27.50 Million | +6.19% |
| 1998-12-31 | $25.90 Million | +8.37% |
| 1997-12-31 | $23.90 Million | +11.16% |
| 1996-12-31 | $21.50 Million | +357.45% |
| 1995-12-31 | $4.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to IRIDEX Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8720900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $174.00K | 8.30% |
| Other Comprehensive Income | $51.00K | 2.43% |
| Other Components | $89.88 Million | 4286.17% |
| Total Equity | $2.10 Million | 100.00% |
IRIDEX Corporation Competitors by Market Cap
The table below lists competitors of IRIDEX Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Xerox Holdings Corporation Warrants
NASDAQ:XRXDW
|
$14.96 Million |
|
ATrack Technology
TWO:6465
|
$14.96 Million |
|
Shanghai Lingyun Industries Development Co Ltd
SHG:900957
|
$14.98 Million |
|
Skolon AB
ST:SKOLON
|
$14.98 Million |
|
China Medical & HealthCare Group Limited
PINK:COLRF
|
$14.95 Million |
|
ProStar Holdings Inc
OTCQX:MAPPF
|
$14.95 Million |
|
Wetteri Oyj
LSE:0G2O
|
$14.95 Million |
|
Adisyn Ltd
AU:AI1
|
$14.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IRIDEX Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 9,522,000 to 2,097,000, a change of -7,425,000 (-78.0%).
- Net loss of 8,910,000 reduced equity.
- New share issuances of 3,370,000 increased equity.
- Other comprehensive income increased equity by 103,000.
- Other factors decreased equity by 1,988,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.91 Million | -424.89% |
| Share Issuances | $3.37 Million | +160.71% |
| Other Comprehensive Income | $103.00K | +4.91% |
| Other Changes | $-1.99 Million | -94.8% |
| Total Change | $- | -77.98% |
Book Value vs Market Value Analysis
This analysis compares IRIDEX Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.43x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.21x to 10.43x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | $1.10 | $1.33 | x |
| 1996-12-31 | $3.44 | $1.33 | x |
| 1997-12-31 | $3.54 | $1.33 | x |
| 1998-12-31 | $3.83 | $1.33 | x |
| 1999-12-31 | $4.02 | $1.33 | x |
| 2000-12-31 | $4.19 | $1.33 | x |
| 2001-12-31 | $4.42 | $1.33 | x |
| 2002-12-31 | $4.36 | $1.33 | x |
| 2003-12-31 | $4.16 | $1.33 | x |
| 2004-12-31 | $4.41 | $1.33 | x |
| 2005-12-31 | $4.38 | $1.33 | x |
| 2006-12-31 | $4.17 | $1.33 | x |
| 2007-12-31 | $2.27 | $1.33 | x |
| 2008-12-31 | $1.33 | $1.33 | x |
| 2009-12-31 | $1.68 | $1.33 | x |
| 2010-12-31 | $1.92 | $1.33 | x |
| 2011-12-31 | $2.19 | $1.33 | x |
| 2012-12-31 | $2.45 | $1.33 | x |
| 2013-12-31 | $2.56 | $1.33 | x |
| 2014-12-31 | $3.26 | $1.33 | x |
| 2015-12-31 | $3.33 | $1.33 | x |
| 2016-12-31 | $3.85 | $1.33 | x |
| 2017-12-31 | $2.64 | $1.33 | x |
| 2018-12-31 | $2.46 | $1.33 | x |
| 2019-12-31 | $1.66 | $1.33 | x |
| 2020-12-31 | $1.25 | $1.33 | x |
| 2021-12-31 | $1.51 | $1.33 | x |
| 2022-12-31 | $1.08 | $1.33 | x |
| 2023-12-31 | $0.59 | $1.33 | x |
| 2024-12-31 | $0.13 | $1.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently IRIDEX Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -424.89%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -18.31%
- • Asset Turnover: 1.67x
- • Equity Multiplier: 13.89x
- Recent ROE (-424.89%) is below the historical average (-27.79%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | 21.28% | 11.36% | 1.38x | 1.36x | $530.00K |
| 1996 | 4.65% | 8.06% | 0.52x | 1.10x | $-1.15 Million |
| 1997 | 8.79% | 11.60% | 0.68x | 1.12x | $-290.00K |
| 1998 | 6.56% | 7.20% | 0.83x | 1.10x | $-890.00K |
| 1999 | 5.88% | 6.05% | 0.82x | 1.19x | $-1.13 Million |
| 2000 | 7.92% | 7.23% | 0.95x | 1.15x | $-634.00K |
| 2001 | -4.27% | -4.67% | 0.81x | 1.13x | $-4.26 Million |
| 2002 | 0.50% | 0.49% | 0.89x | 1.13x | $-2.87 Million |
| 2003 | 1.20% | 1.17% | 0.88x | 1.16x | $-2.71 Million |
| 2004 | -1.26% | -1.23% | 0.84x | 1.23x | $-3.58 Million |
| 2005 | 4.84% | 4.51% | 0.90x | 1.19x | $-1.78 Million |
| 2006 | -17.89% | -16.02% | 0.89x | 1.25x | $-8.97 Million |
| 2007 | -118.41% | -40.11% | 1.19x | 2.48x | $-24.15 Million |
| 2008 | -62.74% | -15.19% | 1.72x | 2.40x | $-8.54 Million |
| 2009 | 17.20% | 5.98% | 1.53x | 1.88x | $1.08 Million |
| 2010 | 15.68% | 6.97% | 1.50x | 1.50x | $1.10 Million |
| 2011 | 11.64% | 7.87% | 1.03x | 1.43x | $367.40K |
| 2012 | 6.56% | 4.25% | 1.17x | 1.32x | $-752.50K |
| 2013 | 8.63% | 5.83% | 1.14x | 1.30x | $-354.40K |
| 2014 | 29.75% | 23.45% | 1.02x | 1.24x | $6.66 Million |
| 2015 | 1.41% | 1.14% | 1.00x | 1.24x | $-2.89 Million |
| 2016 | -29.91% | -25.38% | 0.96x | 1.23x | $-15.63 Million |
| 2017 | -42.16% | -30.94% | 1.00x | 1.36x | $-15.92 Million |
| 2018 | -42.77% | -30.08% | 1.02x | 1.39x | $-15.81 Million |
| 2019 | -38.82% | -20.28% | 1.25x | 1.53x | $-11.08 Million |
| 2020 | -36.44% | -17.41% | 1.30x | 1.61x | $-8.07 Million |
| 2021 | -22.43% | -9.69% | 1.11x | 2.09x | $-7.55 Million |
| 2022 | -43.80% | -13.25% | 1.35x | 2.45x | $-9.27 Million |
| 2023 | -100.50% | -18.45% | 1.51x | 3.62x | $-10.52 Million |
| 2024 | -424.89% | -18.31% | 1.67x | 13.89x | $-9.12 Million |
Industry Comparison
This section compares IRIDEX Corporation's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IRIDEX Corporation (IRIX) | $4.68 Million | 21.28% | 5.06x | $14.96 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |